Research and Markets: The Development of Specific Model Systems Suited for Specific Disease Areas (Such as Oncology) is an Unmet Need
DUBLIN, Ireland, June 8 /PRNewswire/ — Research and Markets (http://www.researchandmarkets.com/reports/c18782 ) has announced the addition of Model Organisms in Drug Discovery and Development: An Industry Analysis to their offering.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )
‘Model Organisms in Drug Discovery and Development: An Industry Analysis’ maps the market opportunity and trends apparent in the model organisms’ space as they relate to drug discovery and development. The report provides comparisons of the various model organisms being deployed currently by the pharmaceutical and biotechnology companies. It also presents the value proposition presented by each of the model systems to the drug discovery and development marketplace. Key company profiles are included to illustrate the scope of offering of the various players, technology platforms utilized, and business model deployed, in the model organisms’ space.
In many ways, the model organisms’ marketplace is a new paradigm in the interrogation, analysis, and screening of biological [drug] targets and lead compounds in a physiologically-relevant context, as opposed to this analysis being performed in a classical in vitro assay.
Eight topics are addressed in the model organisms’ space in this report:
1. Current and emerging model organisms of value in drug discovery and development
2. Comparisons of the various model organisms being deployed currently by the pharmaceutical and biotechnology companies
3. Value proposition presented by each of the model systems to the drug discovery and development marketplace
4. Key emerging model systems for drug discovery and development- Caenorhabditis elegans and Zebrafish (Danio rerio) and the value they provide for drug discovery
5. Qualitative and quantitative market trends in the model organisms’ space. This is based upon an end-user survey of 333 individuals that are participating in drug discovery and development
6. Intellectual property (IP) trends in the model organisms space
7. Quantitative market analysis-top-down and bottom-up market models- presenting the size and growth of the model organisms marketplace
8. Profiles of the key companies in the model organisms’ space. These profiles are designed to illustrate the scope of offering of the various players, technology platforms utilized, and business model deployed, in the model organisms’ space
Companies profiled:
AVEO Pharmaceuticals, Inc.
BioMarker Pharmaceuticals, Inc.
Cambria Biosciences
Chronogen
Danio Labs
Devgen
Discovery Genomics
Exelixis
ARTEMIS Pharmaceuticals GmbH
Ingenium Pharmaceuticals AG
Lexicon Genetics Inc.
Phenomix
Phylonix Pharmaceuticals, Inc.
Union Biometrica
Xenogen
Zygogen, LLC
For more information visit
http://www.researchandmarkets.com/reports/c18782
